文献速递神经肌肉病

利妥昔单抗治疗新发全身型重症肌无力的疗效与安全性:RINOMAX随机临床试验

Efficacy and Safety of Rituximab for New-Onset Generalized Myasthenia Gravis: The RINOMAX Randomized Clinical Trial.
PubMed 文献 · JAMA Neurol · 2022-01-01

这项在瑞典7家区域诊所开展的随机双盲安慰剂对照研究,纳入新发全身型重症肌无力患者,比较单次静脉输注500 mg利妥昔单抗与安慰剂作为标准治疗附加治疗的疗效与安全性。结果显示利妥昔单抗组达到主要终点(16周时QMG≤4分且泼尼松龙≤10 mg/日且无挽救治疗)的比例为71%,安慰剂组为29%(P=.007;概率比2.48,95%CI 1.20-5.11),且安慰剂组挽救治疗更频繁。作者认为需进一步研究长期获益风险平衡。

要点

  • 利妥昔单抗组71%(17/24)达到主要终点,安慰剂组29%(6/21),P=.007。
  • 概率比2.48(95%CI 1.20-5.11),支持利妥昔单抗组更可能达到最小疾病表现。
  • 挽救治疗:利妥昔单抗组1例(4%),安慰剂组8例(36%)。

核心结论

  • 单次500 mg利妥昔单抗与安慰剂相比,与更高的最小重症肌无力表现概率及更低的挽救药物需求相关。
  • 作者认为需进一步研究该治疗的长期获益风险平衡。

研究设计与样本

  • 随机、双盲、安慰剂对照研究,在瑞典7家区域诊所开展,历时48周。
  • 关键纳入标准:年龄大于18岁、全身症状起病在12个月或以内、QMG评分6分或以上。
  • 筛查时间为2016年10月20日至2020年3月2日。
  • 参与者按1:1随机、不分层,接受单次静脉输注500 mg利妥昔单抗或匹配安慰剂。
  • 共87例潜在合格患者,25例随机至利妥昔单抗组(平均[SD]年龄67.4[13.4]岁;7例[28%]女性),22例随机至安慰剂组(平均[SD]年龄58[18.6]岁;7例[32%]女性)。

主要发现

  • 主要终点(16周时QMG评分4分或以下、泼尼松龙10 mg/日或以下、无挽救治疗)达到比例:利妥昔单抗组71%(17/24)vs 安慰剂组29%(6/21),Fisher精确检验P=.007;概率比2.48(95%CI 1.20-5.11)。
  • 次要终点(16周时MG-ADL和MG-QoL变化与24周时QMG比较)在按方案分析(对挽救治疗进行删失)中组间无差异,但在事后分析(采用最差秩插补考虑挽救治疗)中有利于活性治疗。
  • 挽救治疗在安慰剂组更频繁:利妥昔单抗组1例(4%),安慰剂组8例(36%)。
  • 安慰剂组1例患者发生心肌梗死伴心脏骤停,活性治疗组1例患者发生致死性心脏事件。

局限性

  • 作者指出需进一步研究以解决该治疗的长期获益风险平衡问题。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Rituximab is a third-line option for refractory generalized myasthenia gravis (MG) based on empirical evidence, but its effect in new-onset disease is unknown. OBJECTIVE: To investigate the efficacy and safety of rituximab compared with placebo as an add-on to standard of care for MG. DESIGN, SETTING, AND PARTICIPANTS: This randomized, double-blind, placebo-controlled study took place throughout 48 weeks at 7 regional clinics in Sweden. Key inclusion criteria were age older than 18 years, onset of generalized symptoms within 12 months or less, and a Quantitative Myasthenia Gravis (QMG) score of 6 or more. Patients were screened from October 20, 2016, to March 2, 2020. Key exclusion criteria included pure ocular MG, suspected thymoma, previous thymectomy, and prior noncorticosteroid immunosuppressants or high doses of corticosteroids. INTERVENTIONS: Participants were randomized 1:1 without stratification to a single intravenous infusion of 500 mg of rituximab or matching placebo. MAIN OUTCOMES AND MEASURES: Minimal disease manifestations at 16 weeks defined as a QMG score of 4 or less with prednisolone, 10 mg or less daily, and no rescue treatment. RESULTS: Of 87 potentially eligible patients, 25 were randomized to rituximab (mean [SD] age, 67.4 [13.4] years; 7 [28%] female) and 22 to placebo (mean [SD] age, 58 [18.6] years; 7 [32%] female). Compared with placebo, a greater proportion with rituximab met the primary end point; 71% (17 of 24) in the rituximab group vs 29% (6 of 21) in the placebo group (Fisher exact test P = .007; probability ratio, 2.48 [95% CI, 1.20-5.11]). Secondary end points, comparing changes in Myasthenia Gravis Activities of Daily Living and Myasthenia Gravis Quality of Life at 16 weeks with QMG at 24 weeks did not differ between groups with censoring for rescue treatment (per-protocol analysis) but were in favor of active treatment when rescue treatment was taken into account by worst rank imputation (post hoc analysis). Rescue treatments were also more frequent in the placebo arm (rituximab: 1 [4%]; placebo, 8 [36%]). One patient in the placebo arm had a myocardial infarction with cardiac arrest and 1 patient in the active arm experienced a fatal cardiac event. CONCLUSIONS AND RELEVANCE: A single dose of 500 mg of rituximab was associated with greater probability of minimal MG manifestations and reduced need of rescue medications compared with placebo. Further studies are needed to address long-term benefit-risk balance with this treatment. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02950155.

来源:JAMA Neurol,查看原文。版权归原作者所有。

引用

  1. Piehl F, Eriksson-Dufva A, Budzianowska A, et al. Efficacy and Safety of Rituximab for New-Onset Generalized Myasthenia Gravis: The RINOMAX Randomized Clinical Trial. JAMA Neurol. 2022. PMID: 36121672. doi:10.1001/jamaneurol.2022.2887

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。